Vimarsana
Biggest News Aggregation in the World

Page 2 - Thomas Pieber News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Pieber. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Pieber Today - Breaking & Trending Today

Investegate |Arecor Therapeutics Announcements | Arecor Therapeutics: ARECOR TO HOST KOL WEBINAR - Vimarsana News

Investegate |Arecor Therapeutics Announcements | Arecor Therapeutics: ARECOR TO HOST KOL WEBINAR

Investegate announcements from Arecor Therapeutics, ARECOR TO HOST KOL WEBINAR

Zealand Pharma announces publication of Phase 3 trial - Vimarsana News

Zealand Pharma announces publication of Phase 3 trial

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes 3 , 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that Diabetes Care has published results from its Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. The article is available online, and will appear in Diabetes Care...

Investegate |Zealand Pharma Announcements | Zealand Pharma: Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes - Vimarsana News

Investegate |Zealand Pharma Announcements | Zealand Pharma: Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes

Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes 3 , 2021 – Zealand Pharma A/S (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that Diabetes Care has published results from its Phase 3 trial evaluating dasiglucagon for the treatment of severe hypoglycemia in adults with diabetes. The article is available online, and will appear in Diabetes Care...

JDRF, Lupus Research Alliance and National Multiple Sclerosis Society Join Forces to Decode Common Mechanisms of Autoimmune Diseases - Vimarsana News

JDRF, Lupus Research Alliance and National Multiple Sclerosis Society Join Forces to Decode Common Mechanisms of Autoimmune Diseases

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- JDRF International, the Lupus Research Alliance and the National Multiple Sclerosis Society joined forces to accelerate research and discovery in autoimmunity and are

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus - Vimarsana News

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Posted on 7691 Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation is valid in all 27 countries of the European Union, plus ...